Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract
AbstractIt is well documented that dysregulation of microRNAs is a hallmark of human cancers. Thus, this family of small non-coding regulatory molecules represents an excellent source of sensitive biomarkers. Unique microRNAs expression profiles have been associated with different types and subsets of gastrointestinal tumors including gastroenteropancreatic neuroendocrine tumors (GEP-NETs). GEP-NETs are a heterogeneous group of epithelial neoplasms with neuroendocrine differentiation. At present, early detection and surgical resection of GEP-NETs represent the best chance for a cure. Thus, clinically useful biomarkers for GEP-NETs that strongly correlate with early detection are urgently needed. The purpose of this review is to summarize the role of miRNAs in GEP-NET carcinogenesis and their possible use as novel diagnostic, prognostic and predictive biomarkers.
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Vicentini, C.; Fassan, M.; D'Angelo, E.; Corbo, V.; Silvestris, N.; Nuovo, G.J.; Scarpa, A. Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract. Molecules 2014, 19, 2458-2468.
Vicentini C, Fassan M, D'Angelo E, Corbo V, Silvestris N, Nuovo GJ, Scarpa A. Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract. Molecules. 2014; 19(2):2458-2468.Chicago/Turabian Style
Vicentini, Caterina; Fassan, Matteo; D'Angelo, Edoardo; Corbo, Vincenzo; Silvestris, Nicola; Nuovo, Gerard J.; Scarpa, Aldo. 2014. "Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract." Molecules 19, no. 2: 2458-2468.